SCHEMBL1291513

SCHEMBL1291513

Cc1c(Oc2cccc(/C=C3/SC(=O)NC3=O)c2)ncnc1OC1CCN(c2ncc(Cl)cn2)CC1

nearest known ligand 0.68

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 14/20 0.68
▸ ADAMTS5 Q9UNA0 3/20 0.49
▸ AKR1B1 P15121 2/20 0.46
▸ CNR1 P21554 1/20 0.45
▸ PIM1 P11309 1/20 0.44
▸ PIM2 Q9P1W9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1291512 1.00 GPR119 (0.68) GPR119ADAMTS5AKR1B1CNR1PIM1
SCHEMBL15260780 1.00 GPR119 (0.68) GPR119ADAMTS5AKR1B1CNR1PIM1
SCHEMBL1291666 0.92 GPR119 (0.72) GPR119ADAMTS5AKR1B1PIM1PIM2
SCHEMBL1291669 0.92 GPR119 (0.72) GPR119ADAMTS5AKR1B1PIM1PIM2
SCHEMBL1292032 0.92 GPR119 (0.72) GPR119ADAMTS5AKR1B1PIM1PIM2
SCHEMBL1291598 0.91 GPR119 (0.68) GPR119ADAMTS5AKR1B1PIM1PIM2
SCHEMBL1291601 0.91 GPR119 (0.68) GPR119ADAMTS5AKR1B1PIM1PIM2
SCHEMBL15260484 0.91 GPR119 (0.68) GPR119ADAMTS5AKR1B1PIM1PIM2
SCHEMBL1291533 0.87 GPR119 (0.69) GPR119ADAMTS5AKR1B1CNR1PIM1
SCHEMBL15260285 0.87 GPR119 (0.69) GPR119ADAMTS5AKR1B1CNR1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2625177-B1 NOVEL GPR 119 AGONISTS CADILA HEALTHCARE LTD (IN) 2015-07-29 — — EP claimed
US-8785463-B2 GPR 119 agonists CADILA HEALTHCARE LIMITED (IN) 2014-07-22 — — US claimed
US-20130252980-A1 NOVEL GPR 119 AGONISTS CADILA HEALTHCARE LIMITED (IN) 2013-09-26 — — US claimed
EP-2625177-A1 NOVEL GPR 119 AGONISTS Cadila Healthcare Limited (IN) 2013-08-14 — — EP claimed
WO-2012046249-A1 NOVEL GPR 119 AGONISTS CADILA HEALTHCARE LIMITED (IN) 2012-04-12 — — WO claimed
EP-2625177-B1 NOVEL GPR 119 AGONISTS CADILA HEALTHCARE LTD (IN) 2015-07-29 — — EP disclosed
US-8785463-B2 GPR 119 agonists CADILA HEALTHCARE LIMITED (IN) 2014-07-22 — — US disclosed
US-20130252980-A1 NOVEL GPR 119 AGONISTS CADILA HEALTHCARE LIMITED (IN) 2013-09-26 — — US disclosed
EP-2625177-A1 NOVEL GPR 119 AGONISTS Cadila Healthcare Limited (IN) 2013-08-14 — — EP disclosed
WO-2012046249-A1 NOVEL GPR 119 AGONISTS CADILA HEALTHCARE LIMITED (IN) 2012-04-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252980-A1 NOVEL GPR 119 AGONISTS GPR119, GPR27, GPR4 GPR119 1/4885ADAMTS5 4245/4885AKR1B1 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback